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Introduction
There are lots of effects of auto-inflammatory diseases
(e.g. pain, fatigue, fear of attack, lifelong drug use, being
nervous and angry, problems at school) and those are
quite important to patients but have not been measured
with the outcome instruments currently included in
clinical trials of auto-inflammatory diseases.
Objectives
The aim of this study is to develop and validate a new
multidimensional questionnaire for assessment of children
with auto-inflammatory disease (AID) in standard clinical
care.
Methods
JAIMAR includes 16 parent or patient-centered measures
and four dimensions that assess functional status, pain,
therapeutic compliance and health-related quality of life
(physical, social, school, emotional status) with disease
outcome. The JAIMAR is proposed for use as both a
proxy-report and a patient self-report, with the suggested
age range of 8-18 years for use as a self-report. The study
was conducted both children with FMF and their parents
in seven different paediatric rheumatology centers from
Turkey. To validate the JAIMAR, the Outcome Measures
in Rheumatology Clinical Trials (OMERACT) filter for
outcome measures in rheumatology was applied.
Results
The analysis data set was collected between December
2012 - April 2013 from the parents of 250 children with
FMF in 351 visits and from 179 children in 187 visits.
The median age of the children was 10.64 ± 4.38. The
JAIMAR was found to be feasible and to possess face,
content, criterion and construct validity. Completing
and scoring of the JAIMAR is quick and can be finished
approximately in 15 minutes. The Cronbach’s alpha
coefficient for internal consistency for the JAIMAR
dimensions was between 0.507-0.998. Between the test-
retest scale scores, there is a significant and a positive
correlation from medium level to high level (0.607-
0.966). For construct validity all the factor loadings are
above 0.30. When the criterion validity is considered, we
would say that the correlation level between the each
subscale and the related scale spanned from medium
(r = 0.329, p <0.0001) to large (r =0.894, p <0.0001).
Parents’ proxy-reported and children’s self-reported data
were outstandingly concordant. Cronbach’s alpha values
were between 0.770-0.989.
Conclusion
The development of the JAIMAR introduces a new and
a multi-dimensional approach in pediatric rheumatology
practice. It is a valid tool for children with autoinflam-
matory disease and will help enhance the quality of care
of in this group of patients.
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